PALOMA-3: Investigator-assessed PFS (ITT)
PFS, progression-free survival; HR, hazard ratio; CI, confidence interval
Cristofanilli M, et al. Lancet Oncol 2016)
Number of patients at risk
PAL+FUL
347
281
247
202
91
32
7
1
PBO+FUL 174
112
83
59
22
13
2
100
80
60
40
20
0
2
0
4
6
8
10
12
14
Palbociclib + fulvestrant
Placebo + fulvestrant
PAL + FUL
(N=347)
PBO + FUL
(N=174)
Median PFS
, months
(95% CI)
9.5
(9.2, 11.0)
4.6
(3.5, 5.6)
Hazard ratio
(95% CI)
0.461
(0.360, 0.591)
1-sided p-value
<0.000001
Time (months)
PFS (%)
